戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  used for heart disease, risk beta2-mediated bronchospasm).
2 rity from mild itching of the oral mucosa to bronchospasm.
3  bradycardia, hypotension, hypoglycemia, and bronchospasm.
4  when activated, lead to ASM contraction and bronchospasm.
5 effects including atrioventricular block and bronchospasm.
6             We recorded no increased risk of bronchospasm.
7  perioperative bradycardia, hypotension, and bronchospasm.
8 d from 18 hrs to 5 days during resolution of bronchospasm.
9 R(1) increased and L and C(2) decreased with bronchospasm.
10 monary disease tolerated tecadenoson without bronchospasm.
11 which may predispose to oxidative injury and bronchospasm.
12 perienced neutropenic fever and one had mild bronchospasm.
13 ild asthma subjected to methacholine-induced bronchospasm.
14 erents to elicit symptoms, such as cough and bronchospasm.
15 chest pain, AV conduction abnormalities, and bronchospasm.
16 uctive lung disease and profound, refractory bronchospasm.
17 e effects (OR 0.97, 0.67 to 1.40; p=0.85) or bronchospasm (0.99, 0.66 to 1.48; p=0.95).
18  (10.5%), acute laryngeal edema (9%), severe bronchospasm (2.1%), and six fatal cases (1.8%) were rec
19 w-dose ovalbumin (OVA) only produced a small bronchospasm (~2-fold the basal lung resistance), previo
20 ical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in pat
21     The administration of zileuton inhibited bronchospasm after exercise challenge by 40.75% as compa
22 rse events were reported, except a transient bronchospasm after orotracheal intubation in an asthmati
23            Some patients with asthma develop bronchospasm after the ingestion of aspirin and other no
24 f combined smoke inhalation and burn injury, bronchospasm and acute airway obstruction contribute to
25 mitted to an intensive care unit with severe bronchospasm and an upper respiratory tract infection.
26 eta2-blockade risks causing life-threatening bronchospasm and reduced efficacy of beta2-agonist emerg
27 ith excessive coughing, dyspnoea, and reflex bronchospasm and secretions.
28 ifesting as pruritus, urticaria, angioedema, bronchospasm and shock.
29                                  Events like bronchospasm and stiff chest wall were also tested to de
30 er airway obstruction and complications like bronchospasm and stiff chest wall.
31 e presence of IL-11 correlates with clinical bronchospasm and that IL-11 is a potent inducer of airwa
32 truction resulting from airway inflammation, bronchospasm, and mucus plugging.
33 ators in the development of exercise-induced bronchospasm, and that leukotriene inhibit may have a ro
34 y morbidity (e.g., hypotension, bradycardia, bronchospasm, and/or congestive heart failure).
35 t 7 postoperative days, including pneumonia, bronchospasm, atelectasis, pulmonary congestion, respira
36 ostol and PGE2 effectively blocked the acute bronchospasm caused by a subsequent inhaled antigen chal
37 tive cardiorespiratory reflexes (e.g. cough, bronchospasm, changes in respiratory drive and heart rat
38                                              Bronchospasm compresses the bronchial epithelium, and th
39 hoalveolar lavage fluid obtained during this bronchospasm contained increased ATP concentration.
40 eceived cisatracurium exhibited intermittent bronchospasm during and after the study period.
41 those of asthma and that, in the presence of bronchospasm during anesthesia, AS should be considered
42 er a HA was associated with a higher risk of bronchospasm during intra-operative AS.
43 patient with preexisting asthma had an acute bronchospasm during the first cycle and was removed from
44 with diurnal peak expiratory flow variation, bronchospasm following exercise, the need for asthma med
45              The role of ATP in the allergic bronchospasm has been scantly studied.
46  subjects with asthma with hyperpnea-induced bronchospasm (HIB).
47 isease progression in six (12%) patients and bronchospasm, hydrocephalus, respiratory failure, and pn
48 ve been reports of bradycardia, hypotension, bronchospasm, hypoglycemia, and electrolyte disturbances
49 These results suggest that the mechanisms of bronchospasm in AS may be different from those of asthma
50 ve beta-blockers because it has less risk of bronchospasm in asthmatics and it comes in a transcutane
51 otides and ectonucleotidases in the allergic bronchospasm in guinea pigs.
52 tion represents a novel approach to managing bronchospasm in obstructive lung diseases.
53 oidal anti-inflammatory drugs (NSAIDs) cause bronchospasm in susceptible patients with asthma, often
54 n requiring treatment other than reversal of bronchospasm in the study laboratory.
55 ntrally and synergistically to modify reflex bronchospasm initiated by airway mechanoreceptor stimula
56 nd functional airway problems (laryngospasm, bronchospasm, insufficient depth of anesthesia and muscl
57                             Exercise-induced bronchospasm is a common clinical problem that is partic
58 st abscess, n = 1; fatigue, n = 1; and cough/bronchospasms, n = 1).
59 ailure, acute respiratory distress syndrome, bronchospasm, new pulmonary infiltrates, pulmonary infec
60 (hypoglycemia, hypotension, bradycardia, and bronchospasm) occurred infrequently, with no significant
61 methacholine bronchoprovocation to mimic the bronchospasm of mild asthma and (2) while breathing on a
62  nonimmediate cutaneous eruptions, and 17 of bronchospasm related to ASA/nonsteroidal anti-inflammato
63 ulmonary complications, including pneumonia, bronchospasm, respiratory failure and prolonged mechanic
64 s with mild asthma with methacholine-induced bronchospasm results in a minor but significant relaxati
65  days, including severe respiratory failure, bronchospasm, suspected pulmonary infection, pulmonary i
66 s are protean (flushing, sweating, diarrhea, bronchospasm), usually misdiagnosed, and reflect secreti
67 ted-receptor-2 (PAR2) results in relief from bronchospasm via airway smooth muscle relaxation.
68 he only factor statistically associated with bronchospasm was a neuromuscular blocking drug, with bot
69        High-grade atrioventricular block and bronchospasm were not observed.
70 or audiometry and no episodes of significant bronchospasm were observed in association with active tr
71 tagonists, which abolished capsaicin-induced bronchospasm, were without effect on baseline cholinergi
72  Nucleotides greatly potentiate the allergic bronchospasm when ectonucleotidases activity is diminish
73 nt had a quickly resolved infusion reaction (bronchospasm), with no subsequent treatment-related seri